S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CANF Can Fite BioPharma Ltd

2.09

0.06 (2.96%)

After Hours

Last Updated: 06:30:57

Delayed by 15 minutes

Enrollment underway in Can-Fite Bio's mid-stage COVID-19 study

To read the full story on Seeking Alpha, click here.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma Ltd News

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Thursday 25 April 2024 (1 week ago) • Business Wire

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Monday 15 April 2024 (3 weeks ago) • Business Wire

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Wednesday 3 April 2024 (1 month ago) • Business Wire

Can-Fite Reports 2023 Financial Results and Clinical Update
Thursday 28 March 2024 (1 month ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 11 March 2024 (2 months ago) • Edgar (US Regulatory)

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Monday 11 March 2024 (2 months ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Wednesday 28 February 2024 (2 months ago) • Business Wire

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Tuesday 30 January 2024 (3 months ago) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 29 January 2024 (3 months ago) • Edgar (US Regulatory)

More Can Fite BioPharma Ltd News Articles

Australian SE All Ordina...

Commonwealth Bank Of Aus...

Woodside Petroleum

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions